 This is a phase I, open-label, randomized study of NY-ESO-l protein with immune adjuvants CpG 7909 and Montanide ISA-51 and NY-ESO-l protein 400μg with immune adjuvants CpG 7909 and Montanide ISA-51 in patients with tumors that often express NY-ESO-1. 